Pharma Industry News

Janssen’s CAR-T shows 100% response rate in multiple myeloma

Longer-term follow-up data from CARTITUDE-1 study show an overall response rate of 100% while 86% experienced a complete responseOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]